Immunome Chief Legal Officer Sandra Stoneman Receives Stock Options and Restricted Stock Units Grant

Executive Equity Grant Details and Vesting Schedule

Sandra Stoneman, serving as Chief Legal Officer and General Counsel of Immunome Inc., received equity compensation consisting of two distinct security types on July 23, 2026. The grant included 38,250 restricted stock units and 76,500 employee stock options, representing a significant addition to her compensation structure. These securities were issued at no monetary cost to the officer, consistent with standard equity award practices in the biopharmaceutical sector.

The vesting structure for the restricted stock units follows a four-year cliff arrangement, with 25 percent of the units vesting and settling into common stock on each anniversary of the grant date, contingent upon Stoneman's continuous service through each vesting date. This vesting schedule encourages employee retention and aligns executive interests with long-term company performance. The stock options contain a more granular vesting schedule, with 25 percent vesting on July 23, 2027, followed by monthly vesting of one thirty-sixth of the remaining shares thereafter, subject to continuous service requirements.

Stock Option Exercise Price and Expiration Timeline

The employee stock options granted to Stoneman carry an exercise price of $22.01 per share, establishing the price at which the officer may purchase common stock upon exercising the options. These options have a standard 10-year life, expiring on July 22, 2036, providing an extended window for potential exercise contingent on the options becoming vested and Immunome's stock price movements relative to the strike price.

The option pricing at $22.01 per share reflects the terms negotiated or established at the time of grant on July 23, 2026. Options that expire out of the money, meaning Immunome's stock price falls below the exercise price, would have no intrinsic value and would likely not be exercised. The extended expiration timeline provides Stoneman with flexibility regarding the timing of any potential exercise, subject to vesting requirements and applicable securities law restrictions.

Beneficial Ownership Position Following the Grant

Following the acquisition of the restricted stock units, Stoneman's direct beneficial ownership of Immunome common stock increased to 43,805 shares. This ownership position includes both fully vested shares and vested RSUs that have settled into common stock, as well as the newly granted RSUs that remain subject to vesting conditions. The disclosure reflects her beneficial ownership as of the transaction date, demonstrating her stake in the company's performance and aligning her interests with other shareholders.

Direct beneficial ownership, as opposed to indirect ownership through trusts or other entities, indicates that Stoneman holds these securities in her personal capacity. The regulatory requirement to report these transactions and ownership levels provides transparency to investors regarding insider shareholdings and potential conflicts of interest. Executive officers' ownership levels can be an indicator of confidence in company prospects, though insider transactions should be evaluated within the broader context of compensation practices and market conditions.

Regulatory Reporting and Insider Trading Compliance

The disclosure was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and significant shareholders to report changes in beneficial ownership. Stoneman's filing as Chief Legal Officer of Immunome triggers these reporting obligations, ensuring public transparency regarding insider transactions. The Form 4 filing, submitted on July 27, 2026, must be made within two business days of the transaction, allowing investors timely access to information about executive equity compensation.

The reporting person confirmed that the transaction was not executed pursuant to a Rule 10b5-1 trading plan, a contractual arrangement that allows insiders to sell securities on a predetermined schedule to avoid accusations of trading on material non-public information. The absence of such a plan notation indicates this was a standard equity grant rather than a planned series of sales, which is typical for annual or periodic compensation awards to company executives.

Equity Compensation as Part of Executive Incentive Strategy

The issuance of both restricted stock units and stock options to a senior executive reflects a hybrid compensation strategy common in biopharmaceutical and technology companies. Restricted stock units provide direct ownership value tied to the company's stock price at vesting, while options offer upside potential if the stock appreciates above the exercise price. This combination balances immediate wealth accumulation through RSU vesting with the opportunity for additional gains through option appreciation.

Compensation committees at public companies typically employ equity grants to attract and retain executive talent, particularly in competitive industries such as biopharmaceuticals. The vesting conditions impose retention requirements on executives, encouraging them to remain with the company through the multi-year vesting periods. By linking a significant portion of executive compensation to stock price performance and retention, companies aim to align management incentives with shareholder value creation and long-term strategic objectives.

Company Context and Officer Role at Immunome

Immunome Inc. operates in the biopharmaceutical sector and maintains its corporate headquarters at 18702 N. Creek Parkway, Suite 100, in Bothell, Washington. The company is listed on the NASDAQ exchange under the ticker symbol IMNM. The role of Chief Legal Officer and General Counsel is a critical position responsible for legal compliance, risk management, regulatory affairs, and corporate governance. The grant of equity compensation to this executive position reflects the company's recognition of the importance of this leadership role in executing its strategic objectives.

Executive management changes, compensation arrangements, and insider transactions can provide investors with insights into company leadership stability and strategic direction. The timing of equity grants, the size of awards, and the exercise prices or vesting terms may reflect management's confidence in near-term and long-term prospects, though such grants are generally part of pre-established compensation plans rather than discretionary awards tied to specific performance events or expectations.

Transaction Documentation and Filing Accuracy

The Form 4 filing, signed by Sandra Stoneman on July 27, 2026, represents an official declaration of the securities transaction under penalty of federal law. Intentional misstatements or omissions in Form 4 filings constitute federal criminal violations subject to penalties under 18 U.S.C. Section 1001 and 15 U.S.C. Section 78ff(a). The precise documentation of the transaction date, security types, quantities, prices, and vesting terms creates a formal record accessible to investors and market participants through the SEC's EDGAR database.

The filing includes detailed explanation of the vesting schedules for both the restricted stock units and the stock options, providing clarity regarding the conditions under which Stoneman will acquire voting and economic rights in these securities. These explanations are required components of Form 4 disclosures, ensuring that investors and market regulators have complete information regarding the nature and timing of insider compensation arrangements.

What Investors Should Monitor Regarding Insider Holdings

Investors monitoring Immunome should track the vesting of these securities and any subsequent sales or exercises by executive officers. As RSUs vest and settle into common stock, they increase Stoneman's direct shareholding and may influence her voting power and interests within the company. Similarly, if and when stock options vest and are exercised, the resulting common stock acquisitions will further increase her ownership stake. Any subsequent sales of these securities, once vested, must be reported in future Form 4 or Form 5 filings.

The exercise price of $22.01 for the stock options may serve as a reference point for evaluating company stock performance relative to executive compensation. If Immunome's stock price significantly exceeds this level, the options become increasingly valuable and provide incentive for continued executive service and performance. Conversely, if the stock price remains below the exercise price through the vesting period, the options may expire unexercised. Changes in beneficial ownership by company executives are often reviewed by investors as potential indicators of insider sentiment regarding company prospects and stock valuation.